WeTrials

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors

What is this study?

This early-stage study tests a new experimental cancer medicine called RMC-4630 in adults. Researchers want to find the safest and most effective dose for treating solid tumor cancers that have not responded to other treatments.

Who can participate?

You may be able to join if you are 18 or older, have an advanced solid tumor that hasn't responded to standard treatments, and are generally well enough to do normal daily activities. People with certain heart, lung, brain, or eye conditions, however, will not be able to participate.

What will happen?

Participants will receive the study medication while doctors closely monitor their safety and how the drug affects their body. The main goal is to test different doses to see which one works best with the fewest side effects.

Where and when?

This study takes place at medical centers in Scottsdale, Arizona, and Duarte and Orange in California, though the current status is not fully specified. You can check with the study team to see if enrollment is currently open.

Key Points
  • 1Tests an experimental cancer drug called RMC-4630
  • 2Designed for adults with advanced solid tumors
  • 3Focuses on finding the safest and most effective dose

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.